Full text is available at the source.
Chimeric antigen receptor T-cell therapy for solid tumors: A review of the intricate mechanisms and potential strategies
T-cell therapy for solid tumors: Understanding how it works and possible improvement strategies
AI simplified
Abstract
Chimeric Antigen Receptor T-cell (CAR-T) therapy has achieved success in hematological malignancies but faces significant challenges in treating solid tumors.
- Solid tumors present unique challenges for CAR-T therapy, including tumor antigen heterogeneity and an immunosuppressive tumor microenvironment.
- Barriers to effective T-cell infiltration include immune evasion by suppressive cytokines and regulatory cells, as well as tumor antigen escape.
- Innovative strategies like multi-antigen targeting constructs and armored CAR-T cells may enhance efficacy by addressing these barriers.
- The use of matrix-degrading enzymes and immune checkpoint inhibitors could help overcome physical and immune-mediated resistance.
- Emerging targets such as B7-H3, Claudin 18.2, and MUC1 are being explored to improve patient selection and therapeutic monitoring.
AI simplified